Screening for unknown mutations by a bioluminescent protein truncation test with homogeneous detection.
J Am Chem Soc
; 132(14): 5091-5, 2010 Apr 14.
Article
en En
| MEDLINE
| ID: mdl-20232860
The protein truncation test (PTT) is important in screening for unknown mutations that cause premature termination of mRNA translation. PTT involves amplification of the interrogated sequence, in vitro transcription/translation, separation of the generated polypeptides, and detection. In this article, we report a bioluminescent protein truncation test, in which the detection of the nascent protein is performed directly in the expression mixture, within seconds, without the need for separation and purification. A DNA fragment encoding apoaequorin is fused, in-frame, downstream of the interrogated sequence. The fusion product is subjected to in vitro, coupled transcription and translation in the presence of coelenterazine. A wild-type DNA template allows translation to continue after the 3' end of the interrogated sequence, producing a chimeric protein whose C-terminal domain is the photoprotein aequorin. Aequorin is detected, with a high sensitivity, by its characteristic Ca(2+)-triggered, flash-type bioluminescent reaction. Active photoprotein is not produced when a truncating mutation is present in the interrogated sequence. As a model, the method was applied to the detection of truncating mutations in the APC gene (adenomatous polyposis coli).
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Aequorina
/
Mediciones Luminiscentes
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
/
Screening_studies
Límite:
Humans
Idioma:
En
Revista:
J Am Chem Soc
Año:
2010
Tipo del documento:
Article
Pais de publicación:
Estados Unidos